Edition:
India

MorphoSys AG (MORG.DE)

MORG.DE on Xetra

83.00EUR
21 Mar 2019
Change (% chg)

€-1.35 (-1.60%)
Prev Close
€84.35
Open
€84.05
Day's High
€84.10
Day's Low
€79.70
Volume
282,395
Avg. Vol
160,317
52-wk High
€124.90
52-wk Low
€76.45

Latest Key Developments (Source: Significant Developments)

MorphoSys AG FY Revenue Rose 14 Percent To 76.4 Million EUR
Thursday, 14 Mar 2019 

March 13 (Reuters) - MorphoSys AG ::FY NET LOSS -56.2 MILLION EUR VERSUS -69.8 MILLION EUR LOSS YEAR AGO.FY REVENUE ROSE 14 PERCENT TO 76.4 MILLION EUR.FY EBIT LOSS EUR 59.1 MILLION VERSUS LOSS OF EUR 67.6 MILLION IN 2017.REVENUES IN 2019 FINANCIAL YEAR ARE EXPECTED TO BE BELOW THOSE ACHIEVED IN 2018.FOR FY 2019, MORPHOSYS EXPECTS TO GENERATE GROUP REVENUES IN RANGE OF EUR 43 MILLION TO EUR 50 MILLION.EXPECTS 2019 EBIT LOSS OF EUR 127 MILLION TO EUR 137 MILLION.  Full Article

Morphosys: Licensee Janssen Receives U.S. FDA Approval For Tremfya(R) One-Press Patient-Controlled Injector For Adults With Moderate-To-Severe Plaque Psoriasis
Wednesday, 27 Feb 2019 

Feb 27 (Reuters) - MORPHOSYS AG ::ANNOUNCES THAT ITS LICENSEE JANSSEN HAS RECEIVED U.S. FDA APPROVAL FOR TREMFYA(R) ONE-PRESS PATIENT-CONTROLLED INJECTOR FOR ADULTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS.  Full Article

Morphosys Announces Settlement In Patent Lawsuit With Janssen And Genmab
Thursday, 31 Jan 2019 

Jan 31 (Reuters) - MorphoSys AG ::ANNOUNCES SETTLEMENT IN PATENT LAWSUIT WITH JANSSEN AND GENMAB.PARTIES TO DISPUTE HAVE AGREED TO DROP MUTUAL CLAIMS RELATED TO THIS LITIGATION.  Full Article

Morphosys Says Its Licensee Janssen Has Expanded Clinical Development Of Guselkumab Into Ulcerative Colitis
Friday, 18 Jan 2019 

Jan 17 (Reuters) - MorphoSys AG ::MORPHOSYS ANNOUNCES THAT ITS LICENSEE JANSSEN HAS EXPANDED CLINICAL DEVELOPMENT OF GUSELKUMAB (TREMFYA(R)) INTO ULCERATIVE COLITIS.MORPHOSYS AG- JANSSEN HAS INITIATED A PROOF-OF-CONCEPT PHASE 2A CLINICAL TRIAL IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS .MORPHOSYS IS ELIGIBLE TO CERTAIN MILESTONE PAYMENTS AND RECEIVES ROYALTIES ON NET SALES OF TREMFYA (R).  Full Article

Morphosys Licensee Janssen Announces Psoriasis Data
Wednesday, 12 Dec 2018 

Dec 12 (Reuters) - MorphoSys AG ::MORPHOSYS'S LICENSEE JANSSEN ANNOUNCES DATA FROM PHASE 3 HEAD-TO-HEAD STUDY ECLIPSE DEMONSTRATING SUPERIORITY OF TREMFYA(R) VERSUS. COSENTYX(R) AS MEASURED BY PASI 90 AT WEEK 48 IN TREATMENT OF PLAQUE PSORIASIS.LICENSEE JANSSEN HAS ANNOUNCED THAT RESULTS FROM ECLIPSE STUDY DEMONSTRATED THAT TREMFYA^(R) (GUSELKUMAB) WAS SUPERIOR TO COSENTYX^(R) (SECUKINUMAB) IN TREATING ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS FOR PRIMARY ENDPOINT OF A PASI 90 RESPONSE AT WEEK 48.  Full Article

Morphosys - Guselkumab Shows Superior Responses To Secukinumab In The Treatment Of Psoriasis
Friday, 7 Dec 2018 

Dec 7 (Reuters) - MorphoSys AG ::DGAP-ADHOC: AD HOC: MORPHOSYS ANNOUNCES THAT ACCORDING TO A PRESENTATION TITLE AT AN UPCOMING CONFERENCE, GUSELKUMAB DEMONSTRATES SUPERIOR LONG-TERM RESPONSES TO SECUKINUMAB AT WEEK 48 IN THE TREATMENT OF MODERATE TO SEVERE PSORIASIS.MORPHOSYS EXPECTS THAT THIS ANNOUNCEMENT RELATES TO AN UPCOMING PRESENTATION OF CLINICAL DATA FROM SO CALLED "ECLIPSE" CLINICAL STUDY.ECLIPSE TRIAL HAS BEEN CONDUCTED BY MORPHOSYS' LICENSEE JANSSEN, COMPARING EFFICACY OF GUSELKUMAB TREMFYA^(R) TO SECUKINUMAB COSENTYX^(R), FOR TREATMENT OF ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS, AT WEEK 48.TREMFYA^(R) IS A HUMAN ANTI-IL-23 MONOCLONAL ANTIBODY DEVELOPED BY JANSSEN THAT WAS GENERATED UTILIZING MORPHOSYS' PROPRIETARY HUCAL ANTIBODY TECHNOLOGY.  Full Article

I-Mab Biopharma, Morphosys Announce China IND Submission Of TJ202/MOR202
Wednesday, 8 Aug 2018 

Aug 7 (Reuters) - MorphoSys AG ::I-MAB BIOPHARMA AND MORPHOSYS ANNOUNCE CHINA IND SUBMISSION OF TJ202/MOR202.MORPHOSYS AG- I-MAB HAS SUBMITTED AN INVESTIGATIONAL NEW DRUG (IND) APPLICATION TO CHINA NATIONAL DRUG ADMINISTRATION (CNDA) FOR TJ202/MOR202.  Full Article

Germany's Morphosys Has Lower Q2 Sales, Greater Oper. Loss
Thursday, 2 Aug 2018 

Aug 1 (Reuters) - MorphoSys AG ::DGAP-NEWS: MORPHOSYS AG REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 REVENUE 8.1 MILLION EUR VERSUS 11.7 MILLION EUR YEAR AGO.MORPHOSYS IS INCREASING ITS FINANCIAL GUIDANCE FOR 2018, EXPECTING REVENUES OF BETWEEN EUR 67 AND 72 MILLION, EBIT OF EUR -55 TO -65 MILLION.MORPHOSYS- CO AND GALAPAGOS ENTERED INTO GLOBAL LICENSE AGREEMENT WITH NOVARTIS FOR MOR106; CO AND GALAPAGOS TO JOINTLY RECEIVE UP-FRONT PAYMENT OF EUR 95 MILLION.CASH POSITION INCREASED TO EUR 450.5 MILLION AS OF JUNE 30, 2018.EARNINGS BEFORE INTEREST AND TAXES (EBIT) IN Q2 2018 AMOUNTED TO EUR -24.1 MILLION (Q2 2017: EUR -15.4 MILLION).2018 EXPENSES FOR PROPRIETARY DEVELOPMENT AND TECHNOLOGY DEVELOPMENT ARE EXPECTED TO BE IN A CORRIDOR OF EUR 87 TO 97 MILLION.  Full Article

Morphosys And Galapagos Sign Global License Agreement For Mor106 With Pharma Partner
Thursday, 19 Jul 2018 

July 19 (Reuters) - GALAPAGOS NV ::REG-MORPHOSYS AND GALAPAGOS SIGN GLOBAL LICENSE AGREEMENT FOR MOR106 WITH TOP PHARMA PARTNER.EXCLUSIVE GLOBAL LICENSE AGREEMENT WITH NOVARTIS ON MOR106.UP-FRONT PAYMENT OF EUR 95 MILLION (USD 111 MILLION*) AND POTENTIAL MILESTONE PAYMENTS OF UP TO APPROXIMATELY EUR 850 MILLION (USD 1 BILLION*).NOVARTIS TO BEAR ALL FUTURE RESEARCH, DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION COSTS.AGREEMENT BETWEEN MORPHOSYS, GALAPAGOS, AND NOVARTIS IS SUBJECT TO CLEARANCE BY US ANTITRUST AUTHORITIES UNDER HART-SCOTT-RODINO ACT.ROYALTIES UP TO LOW-TEENS TO LOW-TWENTIES.  Full Article

Annual General Meeting Of Morphosys AG Elects New Supervisory Board Members
Friday, 18 May 2018 

May 17 (Reuters) - MorphoSys AG ::DGAP-NEWS: ANNUAL GENERAL MEETING OF MORPHOSYS AG ELECTS NEW SUPERVISORY BOARD MEMBERS.SHAREHOLDERS APPROVED ALL RESOLUTIONS PROPOSED BY COMPANY'S MANAGEMENT AT ITS ANNUAL GENERAL MEETING ON THURSDAY.PROPOSAL APPROVED INCLUDE APPOINTMENT OF PRICEWATERHOUSECOOPERS AG AS AUDITOR FOR 2018 FINANCIAL YEAR.  Full Article

German biotech group Morphosys seeks European partner for debut drug

FRANKFURT, Feb 25 German biotech firm Morphosys is in talks with potential partners to bring its debut drug, a therapeutic antibody against leukaemia, to Europe.